{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:16:33Z","timestamp":1770977793615,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4782-y","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T18:46:56Z","timestamp":1537555616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["PEG-L-CHOP treatment is safe and effective in adult extranodal NK\/T-cell lymphoma with a low rate of clinical hypersensitivity"],"prefix":"10.1186","volume":"18","author":[{"given":"Wen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"issue":"11","key":"4782_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3109\/10428190903186502","volume":"50","author":"H Kohrt","year":"2009","unstructured":"Kohrt H, Advani R. Extranodal natural killer\/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymph. 2009;50(11):1773\u201384.","journal-title":"Leuk Lymph"},{"issue":"12","key":"4782_CR2","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","volume":"19","author":"YL Kwong","year":"2005","unstructured":"Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186\u201394.","journal-title":"Leukemia"},{"issue":"8","key":"4782_CR3","first-page":"3258","volume":"44","author":"B Sharma","year":"1984","unstructured":"Sharma B, Vaziri ND. Augmentation of human natural killer cell activity by cyclophosphamide in vitro. Cancer Res. 1984;44(8):3258\u201361.","journal-title":"Cancer Res"},{"issue":"25","key":"4782_CR4","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse E, Kwong YL. How I treat NK\/T-cell lymphomas. Blood. 2013;121(25):4997\u20135005.","journal-title":"Blood"},{"issue":"4","key":"4782_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4782_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/cncr.11908","volume":"100","author":"CC Li","year":"2004","unstructured":"Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma. Cancer. 2004;100(2):366\u201375.","journal-title":"Cancer"},{"issue":"5","key":"4782_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12185-012-1189-4","volume":"96","author":"M Yamaguchi","year":"2012","unstructured":"Yamaguchi M. Current and future management of NK\/T-cell lymphoma based on clinical trials. Int J Hematol. 2012;96(5):562\u201371.","journal-title":"Int J Hematol"},{"issue":"7","key":"4782_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-008-0669-3","volume":"88","author":"W Yong","year":"2009","unstructured":"Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J. L-asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol. 2009;88(7):647\u201352.","journal-title":"Ann Hematol"},{"issue":"5","key":"4782_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11912-012-0245-9","volume":"14","author":"R Suzuki","year":"2012","unstructured":"Suzuki R. NK\/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep. 2012;14(5):395\u2013402.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"4782_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","volume":"94","author":"M Kim","year":"2015","unstructured":"Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III\/IV NK\/T cell-lymphoma, nasal type (NTCL). Ann Hematol. 2015;94(3):437\u201344.","journal-title":"Ann Hematol"},{"issue":"1","key":"4782_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.seminhematol.2013.11.007","volume":"51","author":"R Suzuki","year":"2014","unstructured":"Suzuki R. Pathogenesis and treatment of extranodal natural killer\/T-cell lymphoma. Semin Hematol. 2014;51(1):42\u201351.","journal-title":"Semin Hematol"},{"issue":"4","key":"4782_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH. Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4782_CR13","first-page":"600","volume":"7","author":"M Earl","year":"2009","unstructured":"Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009;7(9):600\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"4782_CR14","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","volume":"109","author":"M Wetzler","year":"2007","unstructured":"Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and leukemia group B study 9511. Blood. 2007;109(10):4164\u20137.","journal-title":"Blood"},{"issue":"1","key":"4782_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1517\/14712590802586058","volume":"9","author":"A Zeidan","year":"2009","unstructured":"Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9(1):111\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"4782_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","volume":"115","author":"LB Silverman","year":"2010","unstructured":"Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351\u20133.","journal-title":"Blood"},{"issue":"8","key":"4782_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","volume":"12","author":"PA Dinndorf","year":"2007","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991\u20138.","journal-title":"Oncologist"},{"issue":"7","key":"4782_CR18","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744\u201350.","journal-title":"Blood"},{"issue":"12","key":"4782_CR19","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, et al. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymph. 2011;52(12):2237\u201353.","journal-title":"Leuk Lymph"},{"key":"4782_CR20","doi-asserted-by":"crossref","unstructured":"Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, et al. Comparison of native Escherichia Coli L-Asparaginase versus Pegylated Asparaginase, in combination with Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP), in Extranodal NK\/T cell lymphoma, nasal type (NTCL). Cancer Res Treat. 2018;50(3):670\u201380.","DOI":"10.4143\/crt.2017.051"},{"issue":"2","key":"4782_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4149\/neo_2014_029","volume":"61","author":"L Li","year":"2014","unstructured":"Li L, Zhang C, Zhang L, Li X, Wu JJ, Sun ZC, Fu XR, Wang XH, Chang Y, Wang R, et al. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer\/T-cell lymphoma. Neoplasma. 2014;61(2):225\u201332.","journal-title":"Neoplasma"},{"issue":"2","key":"4782_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3892\/or.2014.3237","volume":"32","author":"Y Li","year":"2014","unstructured":"Li Y, Zhang X, Hu T, Han L, Li R, Wen J, Zhang M. Asparagine synthetase expression and its potential prognostic value in patients with NK\/T cell lymphoma. Oncol Rep. 2014;32(2):853\u20139.","journal-title":"Oncol Rep"},{"issue":"46","key":"4782_CR23","first-page":"3257","volume":"92","author":"LY Ping","year":"2012","unstructured":"Ping LY, Zheng W, Wang XP, Xie Y, Lin NJ, Tu MF, Ying ZT, Zhang C, Liu WP, Deng LJ, et al. Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma. Zhonghua Yi Xue Za Zhi. 2012;92(46):3257\u201360.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"15","key":"4782_CR24","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.7314\/APJCP.2014.15.15.6275","volume":"15","author":"JY Wen","year":"2014","unstructured":"Wen JY, Li M, Li X, Chen J, Lin Q, Ma XK, Dong M, Wei L, Chen ZH, Wu XY. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK\/T-cell lymphoma: a pilot study. Asian Pac J Cancer Prev. 2014;15(15):6275\u201381.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"4782_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"key":"4782_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-8722-6-44","volume":"6","author":"N Lin","year":"2013","unstructured":"Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, Ping L, Ying Z, Zhang C, Deng L, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type. J Hematol Oncol. 2013;6:44.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4782_CR27","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"issue":"15","key":"4782_CR28","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973\u201380.","journal-title":"Blood"},{"issue":"20","key":"4782_CR29","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","volume":"7","author":"JH Wang","year":"2016","unstructured":"Wang JH, Wang L, Liu CC, Xia ZJ, Huang HQ, Lin TY, Jiang WQ, Lu Y. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma. Oncotarget. 2016;7(20):29092\u2013101.","journal-title":"Oncotarget"},{"key":"4782_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2016.05.004","volume":"47","author":"XM Jing","year":"2016","unstructured":"Jing XM, Zhang ZH, Wu P, Zhang SC, Ren YR, Xiong ZJ, Wei W, Luo L, Li L. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)\/T cell lymphoma. Leuk Res. 2016;47:26\u201331.","journal-title":"Leuk Res"},{"issue":"2","key":"4782_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/cncr.27752","volume":"119","author":"L Wang","year":"2013","unstructured":"Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer. 2013;119(2):348\u201355.","journal-title":"Cancer"},{"issue":"3","key":"4782_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1365-2249.1990.tb08105.x","volume":"79","author":"LS Stewart","year":"1990","unstructured":"Stewart LS, Sewell HF, Thomson AW. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat. Clin Exp Immunol. 1990;79(3):416\u201323.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"4782_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5606\/kbbihtisas.2012.053","volume":"22","author":"YB Youssef","year":"2012","unstructured":"Youssef YB, Bougmiza I, Bouabid Z, Achour B, Regaieg H, Sriha B, Belkadhi M, Omri HE, Khelif A. Nasopharyngeal\/nasal type NK\/T lymphoma: analysis of 23 cases and current review of the literature. Kulak Burun Bogaz Ihtisas Derg. 2012;22(5):275\u201383.","journal-title":"Kulak Burun Bogaz Ihtisas Derg"},{"issue":"4","key":"4782_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bjorl.2014.05.013","volume":"80","author":"MM Miyake","year":"2014","unstructured":"Miyake MM, Oliveira MV, Miyake MM, Garcia JO, Granato L. Clinical and otorhinolaryngological aspects of extranodal NK\/T cell lymphoma, nasal type. BrazJ Otorhinolaryngol. 2014;80(4):325\u20139.","journal-title":"BrazJ Otorhinolaryngol"},{"issue":"13","key":"4782_CR35","first-page":"773","volume":"81","author":"W Yong","year":"2001","unstructured":"Yong W, Zheng W, Zhang Y. Clinical characteristics and treatment of midline nasal and nasal type NK\/T cell lymphoma. Zhonghua Yi Xue Za Zhi. 2001;81(13):773\u20135.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"4782_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/10428190601059795","volume":"48","author":"B Wang","year":"2007","unstructured":"Wang B, Lu JJ, Ma X, Guo Y, Lu H, Hong X, Li J. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma. 2007;48(2):396\u2013402.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4782_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"4782_CR38","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1128\/JVI.78.10.5007-5014.2004","volume":"78","author":"CM Borza","year":"2004","unstructured":"Borza CM, Morgan AJ, Turk SM, Hutt-Fletcher LM. Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection. J Virol. 2004;78(10):5007\u201314.","journal-title":"J Virol"},{"issue":"1","key":"4782_CR39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/AEM.35.1.172-178.1978","volume":"35","author":"F Klein","year":"1978","unstructured":"Klein F, Rosensteel JF, Hummer RM, Hillman EA, Riggs CW, Charmella LJ. Large-scale production and concentration of infectious Epstein-Barr virus. Appl Environ Microbiol. 1978;35(1):172\u20138.","journal-title":"Appl Environ Microbiol"},{"issue":"6","key":"4782_CR40","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1128\/AEM.40.6.1044-1048.1980","volume":"40","author":"GP Shibley","year":"1980","unstructured":"Shibley GP, Manousos M, Munch K, Zelljadt I, Fisher L, Mayyasi S, Harewood K, Stevens R, Jensen KE. New method for large-scale growth; and concentration of the Epstein-Barr viruses. Appl Environ Microbiol. 1980;40(6):1044\u20138.","journal-title":"Appl Environ Microbiol"},{"issue":"23","key":"4782_CR41","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","volume":"118","author":"R Suzuki","year":"2011","unstructured":"Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018\u201322.","journal-title":"Blood"},{"issue":"3","key":"4782_CR42","first-page":"316","volume":"54","author":"C Ogawa","year":"2013","unstructured":"Ogawa C, Manabe A, Ohara A, Ishiguro A. Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia. Rinsho ketsueki. 2013;54(3):316\u20138.","journal-title":"Rinsho ketsueki"},{"key":"4782_CR43","doi-asserted-by":"crossref","unstructured":"Neumann DR, Marini BL, Phillips TJ, Wilcox RA, Mayer TL, Brown A, Perissinotti AJ. Pegasparaginase silent inactivation during therapy for NK\/T cell lymphoma. Leuk Lymphoma. 2018;59(7):1596\u2013605.","DOI":"10.1080\/10428194.2017.1393672"},{"issue":"1","key":"4782_CR44","first-page":"29","volume":"29","author":"Cooperation Group of Phase IICToPEGA","year":"2008","unstructured":"Cooperation Group of Phase IICToPEGA. Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2008;29(1):29\u201333.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4782-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T15:03:51Z","timestamp":1605020631000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4782"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4782-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"16 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Peking University Beijing Cancer Hospital Ethics Review Committee (reference number: 2011101104), and all procedures were conducted in accordance with ethical principles. The written informed consent was obtained from all individual participants included in the study. The written consent including the nature of the disease, its treatment options, and its possible outcomes was also informed to the patients registered for the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"910"}}